Empowered Funds LLC Invests $5.68 Million in ADMA Biologics, Inc. (NASDAQ:ADMA)

Empowered Funds LLC acquired a new stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 331,209 shares of the biotechnology company’s stock, valued at approximately $5,680,000. Empowered Funds LLC owned about 0.14% of ADMA Biologics as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. SMART Wealth LLC purchased a new stake in ADMA Biologics during the 4th quarter valued at $208,000. State of Alaska Department of Revenue grew its holdings in shares of ADMA Biologics by 1.0% in the fourth quarter. State of Alaska Department of Revenue now owns 134,346 shares of the biotechnology company’s stock worth $2,304,000 after acquiring an additional 1,337 shares during the period. Bleakley Financial Group LLC lifted its holdings in ADMA Biologics by 63.5% in the fourth quarter. Bleakley Financial Group LLC now owns 16,739 shares of the biotechnology company’s stock valued at $287,000 after acquiring an additional 6,498 shares during the period. Calamos Advisors LLC boosted its position in ADMA Biologics by 7.1% in the fourth quarter. Calamos Advisors LLC now owns 425,906 shares of the biotechnology company’s stock worth $7,304,000 after purchasing an additional 28,154 shares during the last quarter. Finally, Jennison Associates LLC grew its stake in shares of ADMA Biologics by 29.3% during the 4th quarter. Jennison Associates LLC now owns 44,640 shares of the biotechnology company’s stock valued at $766,000 after purchasing an additional 10,125 shares during the period. Institutional investors own 75.68% of the company’s stock.

ADMA Biologics Stock Down 4.7 %

ADMA stock opened at $15.88 on Wednesday. The business’s 50-day moving average price is $17.58 and its 200-day moving average price is $17.75. The stock has a market cap of $3.75 billion, a P/E ratio of 56.71 and a beta of 0.75. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a twelve month low of $5.02 and a twelve month high of $23.64.

Insiders Place Their Bets

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the sale, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.70% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

ADMA has been the topic of several recent research reports. HC Wainwright increased their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James increased their price target on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.